Jeffrey G. Spragens - 20 May 2022 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Role: Director
Signature: /s/ Jeffrey G. Spragens
Issuer symbol: SABS
Transactions as of: 20 May 2022
Net transactions value: $0
Form type: 4
Filing time: 23 May 2022, 17:52:37 UTC
Previous filing: 05 Oct 2021
Next filing: 09 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SABS	Common Stock	Other	$0	+299,002	+2300%	$0.000000	312,002	20 May 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person received 207,001 shares as part of a pro-rata distribution by Big Cypress Holdings LLC, which the Reporting Person is a limited partner of, of which shares he previously had an indirect pecuniary interest. Therefore, the transaction, which only changes the form of the Reporting Person's ownership without increasing or decreasing his pecuniary interest, is exempt from the reporting requirements of Section 16 pursuant to Rule 16a-13. Notwithstanding, the Reporting Person is reporting the acquisition on a voluntary basis.

Content

The Reporting Person received 207,001 shares as part of a pro-rata distribution by Big Cypress Holdings LLC, which the Reporting Person is a limited partner of, of which shares he previously had an indirect pecuniary interest. Therefore, the transaction, which only changes the form of the Reporting Person's ownership without increasing or decreasing his pecuniary interest, is exempt from the reporting requirements of Section 16 pursuant to Rule 16a-13. Notwithstanding, the Reporting Person is reporting the acquisition on a voluntary basis.